



## Allopregnanolone in the brain: Protecting pregnancy and birth outcomes



Paula J. Brunton <sup>a,\*</sup>, John A. Russell <sup>b</sup>, Jonathan J. Hirst <sup>c</sup>

<sup>a</sup> Division of Neurobiology, The Roslin Institute, Royal (Dick) School of Veterinary Studies, University of Edinburgh, Scotland, UK

<sup>b</sup> Centre for Integrative Physiology, School of Biomedical Sciences, University of Edinburgh, Scotland, UK

<sup>c</sup> Mothers and Babies Research Centre, School of Biomedical Sciences, University of Newcastle, Newcastle, N.S.W., Australia

### ARTICLE INFO

#### Article history:

Received 29 May 2013

Received in revised form 12 August 2013

Accepted 25 August 2013

Available online 4 September 2013

#### Keywords:

5 $\alpha$ -Reductase

Endogenous opioids

GABA<sub>A</sub> receptor

Gestation

Hypothalamo-pituitary-adrenal axis

### ABSTRACT

A successful pregnancy requires multiple adaptations in the mother's brain that serve to optimise foetal growth and development, protect the foetus from adverse prenatal programming and prevent premature delivery of the young. Pregnancy hormones induce, organise and maintain many of these adaptations. Steroid hormones play a critical role and of particular importance is the progesterone metabolite and neurosteroid, allopregnanolone. Allopregnanolone is produced in increasing amounts during pregnancy both in the periphery and in the maternal and foetal brain. This review critically examines a role for allopregnanolone in both the maternal and foetal brain during pregnancy and development in protecting pregnancy and birth outcomes, with particular emphasis on its role in relation to stress exposure at this time. Late pregnancy is associated with suppressed stress responses. Thus, we begin by considering what is known about the central mechanisms in the maternal brain, induced by allopregnanolone, that protect the foetus(es) from exposure to harmful levels of maternal glucocorticoids as a result of stress during pregnancy. Next we discuss the central mechanisms that prevent premature secretion of oxytocin and consider a role for allopregnanolone in minimising the risk of preterm birth. Allopregnanolone also plays a key role in the foetal brain, where it promotes development and is neuroprotective. Hence we review the evidence about disruption to neurosteroid production in pregnancy, through prenatal stress or other insults, and the immediate and long-term adverse consequences for the offspring. Finally we address whether progesterone or allopregnanolone treatment can rescue some of these deficits in the offspring.

© 2013 Elsevier Ltd. All rights reserved.

### Contents

1. Introduction .....	107
1.1. Neurosteroids and the brain .....	108
1.2. Allopregnanolone and potentiation of inhibitory GABA actions .....	108
1.3. Progesterone and allopregnanolone in the periphery and brain during pregnancy .....	109
1.3.1. Essential role of progesterone .....	109
1.3.2. Allopregnanolone .....	109
1.3.3. Neurosteroidogenic enzymes .....	109

**Abbreviations:** 3 $\alpha$ HSD, 3 $\alpha$ -hydroxysteroid dehydrogenase; ACTH, adrenocorticotrophic hormone; AgRP, agouti-related peptide; AVP, arginine vasopressin; CCK, cholecystokinin; CB1, cannabinoid receptor type 1; CeA, central nucleus of the amygdala; cGMP, cyclic guanosine monophosphate; CRH, corticotropin releasing hormone; CRH-R1, corticotropin releasing hormone receptor type 1; CRH-R2, corticotropin releasing hormone receptor type 2; DA, dopamine; DAP, depolarising after-potential; DHP, dihydroprogesterone; eCB, endocannabinoids; ER, estrogen receptor; GABA, gamma-aminobutyric acid; GR, glucocorticoid receptor; HPA, hypothalamo-pituitary-adrenal; i.c.v., intracerebroventricular; IL-1 $\beta$ , interleukin-1 $\beta$ ; IUGR, intrauterine growth restriction; MAP-2, microtubular associated protein-2; MBP, myelin basic protein; MC-2, melanocortin-2; MCNs, magnocellular neurones; MPOA, medial preoptic area; MR, mineralocorticoid receptor; nNOS, neuronal nitric oxide synthase; NO, nitric oxide; NPY, neuropeptide Y; NTS, nucleus tractus solitarius; ORL1, opioid receptor-like receptor; OTR, oxytocin receptor; pENK-A, proenkephalin-A; PNS, prenatally stressed; POMC, pro-opiomelanocortin; PR, progesterone receptor; PRP, prolactin releasing peptide; PVN, paraventricular nucleus; pPVN, parvocellular subdivision of the paraventricular nucleus; V1b, vasopressin receptor type 1b.

\* Corresponding author at: The Roslin Institute, University of Edinburgh, Easter Bush Campus, Midlothian EH25 9RG, Scotland, UK. Tel.: +44 0131 651 9129; fax: +44 0131 651 9105.

E-mail address: [p.j.brunton@ed.ac.uk](mailto:p.j.brunton@ed.ac.uk) (P.J. Brunton).

2.	Allopregnanolone and maternal neuroendocrine stress responses in pregnancy .....	111
2.1.	The hypothalamo-pituitary-adrenal axis .....	111
2.1.1.	Stress circuitry and the HPA axis .....	111
2.2.	Maternal HPA axis stress responses in late pregnancy .....	111
2.2.1.	Role of allopregnanolone in HPA axis hyporesponsiveness in pregnancy .....	113
2.2.2.	Allopregnanolone and induction of endogenous opioid inhibitory mechanisms .....	113
2.2.3.	Allopregnanolone and GABA <sub>A</sub> receptor interactions in pregnancy .....	114
3.	Oxytocin .....	114
3.1.	Functional organisation .....	115
3.1.1.	Magnocellular oxytocin neurones .....	115
3.1.2.	Parvocellular oxytocin neurones .....	115
3.2.	Adjustment of oxytocin neurone activity in pregnancy .....	115
3.2.1.	Preparations for birth and motherhood .....	115
3.2.2.	Restraining oxytocin neurones in pregnancy .....	115
3.3.	Mechanisms of restraint on oxytocin neurones in pregnancy .....	116
3.3.1.	Identifying oxytocin neurones .....	117
3.4.	Neural pathways to oxytocin MCNs .....	117
3.4.1.	Anatomically defined pathways .....	117
3.4.2.	Neurotransmitters/modulators .....	117
3.5.	Auto-regulation of oxytocin MCNs .....	118
3.5.1.	Soma and dendrites .....	118
3.5.2.	Nitric oxide .....	118
3.5.3.	Endocannabinoids .....	118
3.5.4.	Axon terminals in the posterior pituitary .....	118
3.6.	Hormones and inputs in pregnancy .....	118
3.6.1.	Progesterone, allopregnanolone and the timing of parturition .....	118
3.6.2.	Allopregnanolone and GABA actions on oxytocin MCNs in pregnancy .....	119
3.6.3.	GABA <sub>A</sub> receptors on oxytocin MCNs and allopregnanolone actions .....	119
3.7.	Changes in allopregnanolone action in pregnancy .....	119
3.7.1.	Allopregnanolone and dendritic release of oxytocin .....	120
3.8.	Allopregnanolone and emergence of opioid inhibition of oxytocin magnocellular neurones in late pregnancy .....	120
3.8.1.	Opioid actions on oxytocin neurones .....	120
3.8.2.	Chronic opioid action on oxytocin neurones .....	120
3.8.3.	Functional importance in pregnancy .....	121
3.8.4.	Source of endogenous opioid restraining oxytocin MCNs .....	122
3.8.5.	Induction of opioid inhibition in late pregnancy by allopregnanolone .....	122
3.9.	Opioid actions during parturition .....	123
3.9.1.	Regulation of oxytocin secretion .....	123
3.9.2.	Stress during parturition .....	123
4.	Compromised pregnancy and offspring outcomes .....	123
4.1.	Essential roles of neurosteroids in the foetal brain .....	123
4.2.	Effect of foetal growth restriction on steroid-mediated neuroprotection .....	123
4.3.	Adverse foetal outcomes following premature birth .....	124
4.3.1.	Progesterone replacement in preterm neonates .....	125
4.4.	Adverse effects of stress exposure during pregnancy on the offspring .....	126
4.4.1.	Effects of stress/excessive glucocorticoid exposure during pregnancy on the foetus .....	126
4.4.2.	Effects of stress exposure during pregnancy on the offspring in later life .....	127
4.4.3.	Mechanisms of altered HPA axis regulation in prenatally stressed offspring .....	127
4.4.4.	Effects of prenatal stress on anxiety behaviour .....	128
4.4.5.	A role for altered neurosteroidogenesis in prenatally stressed offspring .....	128
4.4.6.	Allopregnanolone and reversal of foetal programming effects .....	129
5.	Conclusions and future perspectives .....	129
	Acknowledgements .....	129
	References .....	129

## 1. Introduction

It is well established that sex steroids, such as oestrogens and progestogens play critical roles in the brain both during development and throughout adult life. They shape and organise the central nervous system (CNS) during development and have activating effects which influence brain function and a variety of behaviours.

Progestogens are a group of steroid hormones that include progesterone and are named as such due to their vital function in maintaining pregnancy i.e. pro-gestational, though they also function in the non-pregnant animal. In females, they are synthesised primarily by the ovaries (corpus luteum), but can

also be produced in the adrenals and liver and during pregnancy by the placenta and serve as precursors for the biosynthesis of other steroids, including estrogens, androgens, glucocorticoids and mineralocorticoids. Progestogens are also produced within the central nervous system where they are commonly referred to as neurosteroids.

Progesterone is present in high levels during gestation and its actions in the uterus that serve to establish and maintain pregnancy, e.g. facilitating blastocyst implantation and maintaining uterine quiescence by reducing myometrial contractility, are well known (Graham and Clarke, 1997). Progesterone also acts in the brain during pregnancy and contributes to the preparation of the neural circuitry involved in the expression of maternal

Download English Version:

<https://daneshyari.com/en/article/4353360>

Download Persian Version:

<https://daneshyari.com/article/4353360>

[Daneshyari.com](https://daneshyari.com)